ATE190614T1 - Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung - Google Patents

Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung

Info

Publication number
ATE190614T1
ATE190614T1 AT94120539T AT94120539T ATE190614T1 AT E190614 T1 ATE190614 T1 AT E190614T1 AT 94120539 T AT94120539 T AT 94120539T AT 94120539 T AT94120539 T AT 94120539T AT E190614 T1 ATE190614 T1 AT E190614T1
Authority
AT
Austria
Prior art keywords
dihydrate
hydrochloride
dimethoxychinazol
tetrahydrofuroyl
amino
Prior art date
Application number
AT94120539T
Other languages
English (en)
Inventor
Regis Borrega
Satoshi Kitamura
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE190614T1 publication Critical patent/ATE190614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94120539T 1993-12-28 1994-12-23 Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung ATE190614T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5353828A JPH07206857A (ja) 1993-12-28 1993-12-28 アルフゾシン塩酸塩の二水和物

Publications (1)

Publication Number Publication Date
ATE190614T1 true ATE190614T1 (de) 2000-04-15

Family

ID=18433498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94120539T ATE190614T1 (de) 1993-12-28 1994-12-23 Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung

Country Status (6)

Country Link
US (1) US5545738A (de)
EP (1) EP0663398B1 (de)
JP (1) JPH07206857A (de)
KR (1) KR100329156B1 (de)
AT (1) ATE190614T1 (de)
DE (1) DE69423459T2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
ES2305848T3 (es) * 2004-09-16 2008-11-01 Hetero Drugs Limited Base cristalina de alfuzosina.
US20070049756A1 (en) * 2005-08-30 2007-03-01 Anumula Raghupathi R Alfuzosin hydrochloride polymorphs
EP1968970A2 (de) * 2005-12-16 2008-09-17 Wockhardt Limited Verfahren zur herstellung von alfuzosin
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
WO2008114272A2 (en) * 2007-03-22 2008-09-25 Cadila Healthcare Limited Process for preparing alpuzosin and crystalline alfuzosin hydrochloride
CN101687859A (zh) 2007-05-04 2010-03-31 阿克塔维什集团Ptc公司 阿呋唑嗪及其盐的制备工艺
WO2009016387A2 (en) 2007-08-02 2009-02-05 Cipla Limited Process for the preparation of alfuzosin hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN114674967B (zh) * 2022-03-25 2022-10-04 邦恩泰(山东)生物医药科技集团股份有限公司 N-甲基-n′-四氢呋喃甲酰基丙二胺草酸盐有关物质的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition

Also Published As

Publication number Publication date
DE69423459T2 (de) 2000-10-26
EP0663398B1 (de) 2000-03-15
US5545738A (en) 1996-08-13
DE69423459D1 (de) 2000-04-20
KR100329156B1 (ko) 2002-11-22
JPH07206857A (ja) 1995-08-08
EP0663398A1 (de) 1995-07-19
KR950017992A (ko) 1995-07-22

Similar Documents

Publication Publication Date Title
DE69423459D1 (de) Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung
ATE410412T1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
ATE163012T1 (de) N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
NO941052L (no) Benzimidazolforbindelser, deres anvendelse og fremstilling
ATE220667T1 (de) Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
ATE132145T1 (de) Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
NO905172L (no) Aminokarbonylkarbamater beslektet med fysostigmin og fremgangsmaate for fremstilling derav.
ATE407127T1 (de) Verfahren zur herstellung von beraprost und dessen salzen
ATE102482T1 (de) Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
ATE325788T1 (de) Kristalle von vitamin d derivaten und verfahren zu ihrer herstellung
ATE194976T1 (de) Verfahren zur herstellung von n-(amidinophenyl pyrrolidin)-n'-beta-alanin-substituierten harnstoffen
DE69319296D1 (de) Verfahren zur Reinigung von roher Clavulansäure
ATE100077T1 (de) 2-hydroxy-3-phenoxypropylaminoverbindungen.
DE60104986D1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
BR9707004A (pt) Composto processo para preparar o mesmo composição farmacêutica utilização do composto e processos para tratamento de doenças do sistema endocinológico e para a manufatura de um medicamento
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
DE59009951D1 (de) Verfahren zur Herstellung von Zwischenprodukten und zur Synthese von N-(2-Hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxypiperidine.
ATE207482T1 (de) Verfahren zur herstellung von n2-arylsulfonyl-l- argininamiden
DE69107561D1 (de) Verfahren zur Herstellung von 4-Methylsulfonylbenzoesäurederivate und Zwischenprodukte.
DE69127960D1 (de) Verfahren zur Herstellung von (S)-vinyl- und (S)-allenyl-Gaba

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties